References
- Chen A, Stecker EA, Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13). DOI:10.1161/JAHA.120.017559
- Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev. 2017;31(1):77–84.
- Moster M, Bolliger D. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. Curr Anesthesiol Rep. 2022;12(2):286–296.
- Clinical Excellence Commission. New south wales clinical excellence commission. In: Guidelines on perioperative management of anticoagulant and antiplatelet agents. Sydney; 2018. p. 13–14. https://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0006/458988/Guidelines-on-perioperative-management-of-anticoagulant-and-antiplatelet-agents.pdf
- Jourdi G, Mansour A, Vayne C, et al. Anticoagulation therapy in France: state-of-the-art in 2020. Annals Blood. 2020;5:3.
- Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469. DOI:10.1001/jamainternmed.2019.2431
- Chan N, Sager PT, Lawrence J, et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J. 2018 May;199:59–67.
- Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010 Jan;8(1):202–204.
- Douketis J, Spyropoulos A, Anderson J, et al. The perioperative anticoagulant use for surgery evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost. 2017;117(12):2415–2424. DOI:10.1160/TH17-08-0553
- Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–833. DOI:10.1056/NEJMoa1501035
- Dubois V, Dincq A-S, Douxfils J, et al. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017; 15(1).
- Fox V, Kleikamp A, Dittrich M, et al. Direct oral anticoagulants and cardiac surgery: a descriptive study of preoperative management and postoperative outcomes. J Thorac Cardiovasc Surg. 2021 May;161(5):1864–1874.e2.
- Godier A, Martin AC, Leblanc I, et al. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015 Oct;136(4):763–768.
- Kaserer A, Kiavialaitis GE, Braun J, et al. Impact of rivaroxaban plasma concentration on perioperative red blood cell loss. Transfusion. 2020;60(1):197–205. DOI:10.1111/trf.15560
- Tripodi A, Marongiu F, Moia M, et al. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Int Emerg Med. 2018;13(7):1029–1036. DOI:10.1007/s11739-018-1854-6
- Verslype C. Evaluation of abnormal liver-enzyme results in asymptomatic patients. Acta Clin Belg. 2004;59(5):285–289.